BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 5421296)

  • 21. Absence of allotypic variation in the autoantigen for thyroid stimulating autoantibodies.
    Knight A; Adams DD
    Clin Exp Immunol; 1983 May; 52(2):317-24. PubMed ID: 6134598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of a LATS-like response by thyroglobulin in the McKenzie assay system.
    Wood LC; Burger A; Peterson M; Ingbar SH
    Endocrinology; 1973 May; 92(5):1538-43. PubMed ID: 4695433
    [No Abstract]   [Full Text] [Related]  

  • 23. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
    Chopra IJ; Solomon DH; Limberg NP
    J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
    [No Abstract]   [Full Text] [Related]  

  • 24. Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland.
    Adams DD; Kennedy TH
    J Clin Endocrinol Metab; 1967 Feb; 27(2):173-7. PubMed ID: 4163610
    [No Abstract]   [Full Text] [Related]  

  • 25. Preparation and binding of antimicrosomal antibody-free LATS, and the effect of iodination on LATS biological activity.
    Mori T; Kriss JP
    J Clin Endocrinol Metab; 1971 Nov; 33(5):813-21. PubMed ID: 5166460
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibition of the long-acting thyroid stimulator (LATS) by soluble thyroid fractions.
    Beall G; Doniach D; Roitt I; el Kabir D
    J Lab Clin Med; 1969 Jun; 73(6):988-99. PubMed ID: 4977698
    [No Abstract]   [Full Text] [Related]  

  • 27. Heterogeneity of long acting thyroid stimulating (LATS)-activity, thyroglobulin antibodies and thyroid microsomal antibodies.
    Adlkofer F; Schleusener H; Uher L; Ananos A
    Acta Endocrinol (Copenh); 1973 Jul; 73(3):483-8. PubMed ID: 4740843
    [No Abstract]   [Full Text] [Related]  

  • 28. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
    Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
    Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
    [No Abstract]   [Full Text] [Related]  

  • 29. Interaction of purified long-acting thyroid stimulator (LATS) and thyroid microsomes in vitro.
    Wong ET; Litman GW
    J Clin Endocrinol Metab; 1969 Jan; 29(1):72-8. PubMed ID: 5762323
    [No Abstract]   [Full Text] [Related]  

  • 30. Neutralization of the long-acting thyroid stimulator by thyroid subcellular fractions.
    Berumen FO; Lobsenz IL; Utiger RD
    J Lab Clin Med; 1967 Oct; 70(4):640-9. PubMed ID: 6072404
    [No Abstract]   [Full Text] [Related]  

  • 31. The Ig class and light chain type of the long acting thyroid stimulator.
    Maisey MN
    Clin Endocrinol (Oxf); 1972 Apr; 1(2):189-98. PubMed ID: 4197893
    [No Abstract]   [Full Text] [Related]  

  • 32. Characterization of the LATS-binding protein from human thyroid tissue.
    Smith BR; Brownstone A; Munro DS
    Proc R Soc Med; 1971 Feb; 64(2):155. PubMed ID: 5548936
    [No Abstract]   [Full Text] [Related]  

  • 33. The interaction of the long-acting thyroid stimulator (LATS) with thyroid tissue in vitro.
    Smith BR
    J Endocrinol; 1970 Jan; 46(1):45-54. PubMed ID: 5412406
    [No Abstract]   [Full Text] [Related]  

  • 34. Stimulation of the human thyroid by infusions of plasma containing LATS protector.
    Adams DD; Fastier FN; Howie JB; Kennedy TH; Kilpatrick JA; Stewart RD
    J Clin Endocrinol Metab; 1974 Nov; 39(5):826-32. PubMed ID: 4425101
    [No Abstract]   [Full Text] [Related]  

  • 35. LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.
    Shishiba Y; Miyachi Y; Takaishi M; Ozawa Y
    J Clin Endocrinol Metab; 1978 May; 46(5):841-8. PubMed ID: 262769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of cryopreserved human thyroid tissue for the in vitro assay of thyroid stimulators.
    Knox AJ; von Westarp C; Row VV; Volpé R
    Cryobiology; 1977 Oct; 14(5):543-8. PubMed ID: 198180
    [No Abstract]   [Full Text] [Related]  

  • 37. The lipolytic activity of long-acting thyroid stimulator.
    Kendall-Taylor P; Munro DS
    Biochim Biophys Acta; 1971 Mar; 231(2):314-9. PubMed ID: 5554904
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of long-acting thyroid stimulator by thyroid particulate fractions.
    Beall GN; Solomon DH
    J Clin Invest; 1966 Apr; 45(4):552-61. PubMed ID: 5937026
    [No Abstract]   [Full Text] [Related]  

  • 39. Failure of immunologic reaction of long acting thyroid stimulator (LATS) to thyroid components, and the demonstration of a plasma inhibitor LATS.
    Burke G
    J Lab Clin Med; 1967 May; 69(5):713-27. PubMed ID: 4960804
    [No Abstract]   [Full Text] [Related]  

  • 40. [LATS production by lymphocyte culture].
    Fukuchi M
    Nihon Naibunpi Gakkai Zasshi; 1969 Oct; 45(7):766-77. PubMed ID: 5394607
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.